Why HUTCHMED (China) Limited’s (HCM) Stock Is Up 5.89%
As of Monday, September 14, HUTCHMED (China) Limited’s HCM share price has surged by 5.89%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Commentary & Analysis
Why HUTCHMED (China) Limited’s (HCM) Stock Is Up 13.21%
As of Thursday, September 03, HUTCHMED (China) Limited’s HCM share price has surged by 13.21%, which has investors questioning if this is right time to sell.Michael Rose
Why HUTCHMED (China) Limited’s (HCM) Stock Is Up 17.44%
As of Thursday, September 03, HUTCHMED (China) Limited’s HCM share price has surged by 17.44%, which has investors questioning if this is right time to sell.Omar Beirat
Why HUTCHMED (China) Limited’s (HCM) Stock Is Up 5.16%
As of Friday, August 07, HUTCHMED (China) Limited’s HCM share price has surged by 5.16%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Is HUTCHMED (China) Limited (HCM) Overvalued?
We dive into why HUTCHMED (China) Limited (HCM) could be considered overvalued on 2026-08-05, based on AAII’s Value Score and Grade.Michael Rose
Financial Summary
| Share Statistics | HCM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,332.4 | $608.6 | 56% |
|
| Shares Out (Mil) | 872.9 | 43.1 | 93% |
|
| Institutional Ownership | 95.3% | 83.7% | 67% |
|
| Float (Mil) | 522.8 | 45.1 | 86% |
|
| Beta | 0.44 | 0.73 | 25% |
|
| Avg Daily Volume (000s) | 132 | 309 | 40% |
|
| Price Change (52-week) |
(16.6%) | 65.2% | 36% |
|
| Growth | HCM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.2% | 6.7% | 80% |
|
| Net Income (5yr) | 41.3% | (1.5%) | 91% |
|
| EPS (5yr) | 37.4% | 15.1% | 87 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (21.3%) | (15.0%) | 31% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | HCM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $549 | $317 | 42% |
|
| Net Income (TTM) (Mil) | $18 | ($11) | 48% |
|
| EPS (TTM) | $0.021 | ($0.700) | 40% |
|
| Operating Cash Flow (TTM) (Mil) | $21 | ($6) | 41% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $5 | 34% |
|
| Long-Term Debt (Q1) (Mil) | $72 | $6 | 42% |
|
| Enterprise Value (Q1) (Mil) | $774 | $524 | 38% |
|
| Valuation | HCM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.42 | 2.60 | 90% |
|
| P/E | 683.0 | 17.0 | 100% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 18.3 | 1.1 | 97% |
|
| Ratios | HCM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 13.3% | 68.8% | 12% |
|
| Net Margin | 3.3% | 0.8% | 42% |
|
| ROA | 1.0% | (22.5%) | 46% |
|
| ROE | 1.4% | (21.8%) | 37% |
|
| Liabilities to Assets | 26.6% | 32.8% | 18% |
|
| F-Score | 6 | 3 | 67% |
|
HUTCHMED (China) Limited did not pass any screens on 9/14/2026.
